Subtopic Deep Dive
Tumor Necrosis Factor Inhibitors in Spondyloarthritis
Research Guide
What is Tumor Necrosis Factor Inhibitors in Spondyloarthritis?
Tumor Necrosis Factor Inhibitors in Spondyloarthritis covers biologic drugs like etanercept and adalimumab that block TNF-alpha to treat ankylosing spondylitis and psoriatic arthritis.
Guidelines from ASAS-EULAR recommend TNF inhibitors as first-line biologics for axial spondyloarthritis after NSAID failure (van der Heijde et al., 2017, 1515 citations; Ramiro et al., 2022, 790 citations). Studies assess efficacy in TNF-naive and experienced patients, with updates incorporating treat-to-target strategies (Smolen et al., 2017, 660 citations). Over 10 key papers since 2005 guide clinical management.
Why It Matters
TNF inhibitors improve BASDAI scores and spinal mobility in ankylosing spondylitis patients, reducing disability and healthcare costs (Dougados et al., 2011, 978 citations). In psoriatic arthritis, they control skin and joint symptoms, with research comparing them to IL-17 inhibitors for non-responders (Gossec et al., 2020, 912 citations). Ward et al. (2019, 666 citations) provide ACR recommendations prioritizing TNF inhibitors based on radiographic progression data, influencing treatment algorithms amid biologic cost pressures.
Key Research Challenges
Identifying Response Predictors
Predicting which patients benefit from TNF inhibitors remains difficult due to heterogeneous spondyloarthritis phenotypes. Smolen et al. (2017, 660 citations) highlight need for biomarkers beyond HLA-B27. Longitudinal data gaps persist (Ritchlin et al., 2014, 653 citations).
Managing Long-term Safety
Infections and malignancy risks require monitoring in long-term TNF inhibitor use. ASAS-EULAR updates address safety in axial SpA cohorts (Ramiro et al., 2022, 790 citations). Comparative safety data against JAK inhibitors is limited (Gossec et al., 2020, 912 citations).
Optimizing Treatment Sequencing
Deciding when to switch from TNF to IL-17 or IL-23 inhibitors lacks consensus. Ward et al. (2019, 666 citations) recommend TNF first-line but note gaps in non-radiographic SpA. Cost-effectiveness analyses are needed (van der Heijde et al., 2017, 1515 citations).
Essential Papers
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen, D. Aletaha, J. W. J. Bijlsma et al. · 2010 · Annals of the Rheumatic Diseases · 2.0K citations
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde, Sofía Ramiro, Robert Landewé et al. · 2017 · Annals of the Rheumatic Diseases · 1.5K citations
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Joseph M. Braun, Rosaline van den Berg, Xenofon Baraliakos et al. · 2011 · Annals of the Rheumatic Diseases · 978 citations
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer et al. · 2020 · Annals of the Rheumatic Diseases · 912 citations
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano et al. · 2022 · Annals of the Rheumatic Diseases · 790 citations
ASAS/EULAR recommendations for the management of ankylosing spondylitis
Jane Zochling, D van der Heijde, R Burgos-Vargas et al. · 2005 · Annals of the Rheumatic Diseases · 703 citations
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward, Atul Deodhar, Lianne S. Gensler et al. · 2019 · Arthritis Care & Research · 666 citations
Objective To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis ( AS ) and nonradiographic axial spondyloarthritis (SpA). Methods We conducted updated s...
Reading Guide
Foundational Papers
Start with Zochling et al. (2005, 703 citations) for core ASAS/EULAR ankylosing spondylitis management, then Dougados et al. (2011, 978 citations) for 2010 update establishing TNF inhibitors as standard.
Recent Advances
Study Ramiro et al. (2022, 790 citations) for latest axial SpA recommendations and Gossec et al. (2020, 912 citations) for psoriatic arthritis updates integrating TNF data.
Core Methods
Treat-to-target using ASDAS/BASDAI (Smolen et al., 2017); randomized trials like PSUMMIT-2 for post-TNF options (Ritchlin et al., 2014).
How PapersFlow Helps You Research Tumor Necrosis Factor Inhibitors in Spondyloarthritis
Discover & Search
Research Agent uses searchPapers('TNF inhibitors ankylosing spondylitis guidelines') to retrieve van der Heijde et al. (2017, 1515 citations), then citationGraph to map ASAS-EULAR updates and findSimilarPapers for comparative trials.
Analyze & Verify
Analysis Agent applies readPaperContent on Ramiro et al. (2022) for 2022 recommendations, verifyResponse with CoVe to check TNF efficacy claims against GRADE evidence levels, and runPythonAnalysis to plot BASDAI response rates from extracted trial data.
Synthesize & Write
Synthesis Agent detects gaps in sequencing TNF to ustekinumab via contradiction flagging across Smolen et al. (2017) and Ritchlin et al. (2014); Writing Agent uses latexEditText, latexSyncCitations for guideline tables, and latexCompile for publication-ready reviews.
Use Cases
"Extract BASDAI improvement rates from TNF inhibitor trials in axial SpA and plot meta-analysis."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis, matplotlib forest plot) → researcher gets CSV of pooled odds ratios and GRADE-verified figure.
"Draft EULAR-style recommendation table comparing TNF vs IL-17 in psoriatic arthritis."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Gossec 2020, Ritchlin 2014) + latexCompile → researcher gets compiled PDF with cited table.
"Find code for simulating TNF inhibitor response predictors from Sieper et al. overview."
Research Agent → paperExtractUrls (Sieper 2002) → paperFindGithubRepo → githubRepoInspect → researcher gets Python scripts for HLA-B27 risk modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TNF inhibitor papers, chaining searchPapers → citationGraph → DeepScan for 7-step GRADE grading of ASAS recommendations (Ramiro 2022). Theorizer generates hypotheses on biomarker predictors from Smolen (2017) and Ward (2019) treat-to-target data. DeepScan verifies safety claims across van der Heijde (2017) and Gossec (2020).
Frequently Asked Questions
What is the definition of TNF inhibitors in spondyloarthritis?
TNF inhibitors are biologics like etanercept and adalimumab that block TNF-alpha to reduce inflammation in ankylosing spondylitis and psoriatic arthritis (van der Heijde et al., 2017).
What methods assess TNF inhibitor efficacy?
BASDAI and ASDAS scores measure response in trials; ASAS-EULAR uses 40% improvement criteria (Dougados et al., 2011, 978 citations).
What are key papers on TNF inhibitors?
Van der Heijde et al. (2017, 1515 citations) and Ramiro et al. (2022, 790 citations) provide ASAS-EULAR guidelines; Ward et al. (2019, 666 citations) offers ACR updates.
What open problems exist?
Biomarker prediction of response and optimal sequencing to non-TNF biologics remain unresolved (Smolen et al., 2017, 660 citations).
Research Spondyloarthritis Studies and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Tumor Necrosis Factor Inhibitors in Spondyloarthritis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers